SCHEMBL22778182

SCHEMBL22778182

FC(F)(F)c1ccc(-c2ccc(-c3cccnc3)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.68
KIF11 P52732 3/20 0.67
S1PR1 P21453 1/20 0.62
NPY5R Q15761 1/20 0.62
CYP2A6 P11509 3/20 0.60
ALDH1A1 P00352 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
DGAT1 O75907 1/20 0.60
KCNH2 Q12809 1/20 0.60
KDR P35968 3/20 0.56
EPHX2 P34913 1/20 0.52
MKNK1 Q9BUB5 3/20 0.52
MKNK2 Q9HBH9 3/20 0.52
CYP11B2 P19099 1/20 0.52
EGFR P00533 1/20 0.50
FGFR1 P11362 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6552315 1.00 NPC1 (0.68) NPC1KIF11S1PR1NPY5RCYP2A6
SCHEMBL29468037 1.00 NPC1 (0.68) NPC1KIF11S1PR1NPY5RCYP2A6
SCHEMBL23045014 0.90 NPC1 (0.57) NPC1KIF11S1PR1NPY5RCYP2A6
SCHEMBL26548400 0.90 CYP11B2 (0.65) NPC1KIF11S1PR1NPY5RDGAT1
SCHEMBL26547967 0.90 CYP11B2 (0.65) NPC1KIF11S1PR1NPY5RDGAT1
SCHEMBL26548584 0.88 CYP11B2 (0.63) NPC1KIF11S1PR1NPY5RCYP2A6
SCHEMBL26548895 0.88 CYP11B2 (0.63) NPC1KIF11S1PR1NPY5RCYP2A6
SCHEMBL14527301 0.84 MKNK1 (0.62) NPC1KIF11S1PR1KDREPHX2
SCHEMBL29164329 0.83 KIF11 (0.56) NPC1KIF11S1PR1NPY5RCYP2A6
SCHEMBL25390854 0.83 KIF11 (0.78) NPC1KIF11CYP2A6ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12115154-B2 Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) SRX CARDIO, LLC (US) 2024-10-15 US disclosed
US-20220267269-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO LLC (US) 2022-08-25 US disclosed
US-20220193058-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC 2022-06-23 US disclosed
US-20220193058-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC 2022-06-23 US disclosed
EP-3983392-A2 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX Cardio, LLC (US) 2022-04-20 EP disclosed
CN-114206843-A Compounds for modulating proprotein convertase subtilisin/Kexin type 9(PCSK9) SRX心脏有限责任公司 2022-03-18 CN disclosed
WO-2020252383-A2 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC (US) 2020-12-17 WO disclosed
WO-2020252383-A2 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC (US) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193058-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 NPC1 119/4885KIF11 3450/4885S1PR1 782/4885
US-12115154-B2 Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) PCSK9, PCSK6, PCSK7 NPC1 119/4885KIF11 3450/4885S1PR1 782/4885
US-20220267269-A1 COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 NPC1 119/4885KIF11 3450/4885S1PR1 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.